EN DE
Watch Pilulka Lekarny as for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Pilulka Lekarny as (PINK) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Pilulka Lekarny as stock CZK 105, price CZK 82.00, upside +28.2%, quality 41 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CZ · ISIN CZ0009009874

PL Pilulka Lekarny as logo Thin data Nov 4, 2026

Pilulka Lekarny as

PINK · PR
Speculative

The stock costs 22% less than our calculation considers fair.

Fair value 105.11 CZK · Undervalued
Quality 41/100
Negative equity (buybacks among others)
Weak Growth (revenue 5y −13.2 %/yr in CZK)
Loss-making · -4.4% net margin (TTM)
Negative free cash flow
Trails peers (2/7)
Narrow moat 5/100 · thin data
Thin data
Watch Pilulka Lekarny as for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

1,781 CZK 82.00 CZK Fair Value 105.11 CZK Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 82.00 CZK – 1,781 CZK · fair‑value band 75.17 CZK – 135.05 CZK · the 82.00 CZK price screens below the 105.11 CZK fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Pilulka Lekarny as in your weekly email

Every Wednesday you see whether Pilulka Lekarny as is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pilulka Lékárny a.s. operates a network of pharmacy stores under the Pilulka brand in the Czech Republic, Slovakia, Romania, Hungary, and Austria.

Show moreShow less

The company distributes medicinal products; online sale of pharmacy and related goods for health; and healthy lifestyle and services under the Pilulka brand. It also operates Internet portals, such as Pilulka.cz, Pilulka.sk, Pilulka.ro, Pilulka.hu, and Pilulka.at, as well as an e-shop.

Pilulka Lékárny a.s. was founded in 2013 and is headquartered in Prague, the Czech Republic.

Stock analysis

Pilulka Lekarny as (PINK) currently trades at 82.00 CZK, while our model-based Fair Value estimate is 105.11 CZK, implying the stock looks roughly 22% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the data coverage at low.

Scenario range: 75.17 CZK (bear) to 135.05 CZK (bull), the price of 82.00 CZK sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Pilulka Lekarny as reported revenue of 876M CZK in FY2025 versus 2.4B CZK in FY2021, a compound −22.1%/yr. Reported net income was −38.9M CZK in FY2025.

Key figures

Market cap 246M CZK (≈ $11.3M) Micro · P/S ratio 0.28 · EPS (TTM) −14.36 CZK · Net margin −4.4% · Return on assets (EBIT) −17.7% (5-year average) · Operating margin −1.9% · Revenue (TTM) 876M CZK · Free cash flow −20.4M CZK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 55% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at 28%, PINK screens cheaper than that median.

Fair Value models

Bear 75.17 CZK Fair Value 105.11 CZK Bull 135.05 CZK
Price 82.00 CZK · Upside +28.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA 75.17 CZK 105.11 CZK 135.05 CZK 67
All 1 models by family
Multiples
EV/EBITDA 75.17 CZK 105.11 CZK 135.05 CZK 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 34
How much profit the company makes from its sales and capital
Quality Growth 41
Are margins and returns getting better?
Cashflow 30
Do the profits arrive as real cash?
Financial strength 9
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 37
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 71
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−32.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−29.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.2%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2.9% (2019) → −1.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch PINK, get fair value alerts →

Compare Pilulka Lekarny as with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside +28.2% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −19.7% · Bottom 25%
Net margin (12 months) −4.4% · Bottom 25%
Operating margin (12 months) −1.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 0.28× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)71 · sector 68
FUTURE (revenue growth)0 · sector 21
PAST (return on equity)0 · sector 32
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 58

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
JD Health International Inc 6618 HK$43.26 HK$75.61 +75% vs PINK
Luyan Pharma Co 002788 ¥9.53 ¥15.91 +67% vs PINK
Yifeng Pharmacy Chain Co 603939 ¥27.07 ¥40.59 +50% vs PINK
Yixintang Pharmaceutical Group 002727 ¥13.48 ¥18.92 +40% vs PINK
DaShenLin Pharmaceutical Group 603233 ¥21.49 ¥25.52 +19% vs PINK
MedPlus Health Services Limited MEDPLUS ₹604.60 ₹707.67 +17% vs PINK
Anhui Huaren Health Pharmaceutical Co 301408 ¥13.81 ¥15.40 +12% vs PINK
LBX Pharmacy Chain Joint Stock Company 603883 ¥14.97 ¥16.43 +10% vs PINK
ShuYu Civilian Pharmacy Corp 301017 ¥14.34 ¥5.91 −59% vs PINK
Apotea AB APOTEA kr 104.30 kr 39.50 −62% vs PINK

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pilulka Lekarny as: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pilulka Lekarny as Fair Value". https://www.fairvalue-calculator.com/stock/PINK

Frequently asked questions

Is Pilulka Lekarny as (PINK) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 105.11 CZK versus a price of 82.00 CZK, about +28% upside (undervalued).
What is the fair value of PINK?
Our model-based fair value for Pilulka Lekarny as is 105.11 CZK (as of Nov 4, 2026), built from audited fundamentals. The current price: 82.00 CZK.
What is the quality score of PINK?
Pilulka Lekarny as has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pilulka Lekarny as (PINK)?
Our model-based price target is the fair value of 105.11 CZK (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 75.17 CZK, optimistic scenario 135.05 CZK. It is a calculation from audited fundamentals, not an analyst target.
What is the Pilulka Lekarny as stock forecast for 2026?
Our models put fair value at 105.11 CZK, about +28% upside versus a price of 82.00 CZK (undervalued). Cautious scenario 75.17 CZK, optimistic scenario 135.05 CZK. The calculation is refreshed regularly with new filings.
What is the revenue of Pilulka Lekarny as (PINK)?
Pilulka Lekarny as reported trailing-twelve-month revenue of about 876M CZK (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Pilulka Lekarny as (PINK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pilulka Lekarny as it is 105.11 CZK per share (as of Nov 4, 2026), against a price of 82.00 CZK. It is the blended result of 1 valuation models in 1 family (Multiples).
Is Pilulka Lekarny as stock overvalued or undervalued in 2026?
As of Nov 4, 2026, PINK trades below its calculated fair value: price 82.00 CZK, fair value 105.11 CZK, a gap of about +28% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PINK?
No. The price is what the market pays today (82.00 CZK); the fair value is what the company's own numbers justify (105.11 CZK). For Pilulka Lekarny as the two are 23.11 CZK per share apart. That gap is exactly why we show both numbers side by side.
How much is Pilulka Lekarny as worth?
The market values Pilulka Lekarny as at about 246M CZK (market capitalisation, as of Nov 4, 2026). Per share that is 82.00 CZK; our models calculate a fair value of 105.11 CZK per share.
What do the bullish and bearish scenarios say about PINK?
Our models span a range for Pilulka Lekarny as: cautious scenario 75.17 CZK, base 105.11 CZK, optimistic 135.05 CZK per share (as of Nov 4, 2026, price 82.00 CZK). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pilulka Lekarny as (PINK)?
Balance-sheet figures for Pilulka Lekarny as (as of Nov 4, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is PINK from its 52-week high?
Pilulka Lekarny as trades at 82.00 CZK, about 55% below its 52-week high of 183.00 CZK and at the low of 82.00 CZK (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 105.11 CZK is for.
Which stocks are comparable to Pilulka Lekarny as?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pilulka Lekarny as stock attractive at the current price?
The data as of Nov 4, 2026: price 82.00 CZK, calculated fair value 105.11 CZK (+28%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PINK calculated?
We run Pilulka Lekarny as through 1 models from 1 family: Multiples. Every model gets the same audited fundamentals; the fair value of 105.11 CZK builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Pilulka Lekarny as currently trades 22% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pilulka Lekarny as (PINK)?
The closing price on Nov 6, 2026 was 82.00 CZK. Our model-based fair value is 105.11 CZK, about +28% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pilulka Lekarny as right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Pilulka Lekarny as

How large is the market capitalisation of Pilulka Lekarny as (PINK)?
The market capitalisation of Pilulka Lekarny as is 246M CZK (≈ $11.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pilulka Lekarny as (PINK)?
The price-to-sales ratio of Pilulka Lekarny as is 0.28 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pilulka Lekarny as (PINK)?
Earnings per share at Pilulka Lekarny as are −14.36 CZK. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pilulka Lekarny as (PINK)?
The net margin of Pilulka Lekarny as is −4.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Pilulka Lekarny as (PINK)?
On an EBIT basis the return on assets of Pilulka Lekarny as is −17.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pilulka Lekarny as (PINK)?
The operating margin of Pilulka Lekarny as is −1.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Pilulka Lekarny as (PINK) generate?
The free cash flow of Pilulka Lekarny as is −20.4M CZK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pilulka Lekarny as (PINK) carry?
The net debt of Pilulka Lekarny as is 39.7M CZK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pilulka Lekarny as in the live analysis

One click puts Pilulka Lekarny as on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.